R. Loch Macdonald Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

R Macdonald ACST stock SEC Form 4 insiders trading

R has made over 5 trades of the Acasti Pharma Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently R exercised 10,000 units of ACST stock worth $23,200 on 15 March 2019.

The largest trade R's ever made was exercising 25,000 units of Acasti Pharma Inc stock on 23 January 2017 worth over $51,000. On average, R trades about 5,455 units every 71 days since 2016. As of 15 March 2019 R still owns at least 580,602 units of Acasti Pharma Inc stock.

You can see the complete history of R Macdonald stock trades at the bottom of the page.

What's R Macdonald's mailing address?

R's mailing address filed with the SEC is 103 CARNEGIE CENTER, SUITE 300, PRINCETON, NJ, 08540.

Insiders trading at Acasti Pharma Inc

Over the last 3 years, insiders at Acasti Pharma Inc have traded over $0 worth of Acasti Pharma Inc stock and bought 676,752 units worth $1,252,067 . The most active insiders traders include Vimal Kavuru, John Canan a R. Loch Macdonald. On average, Acasti Pharma Inc executives and independent directors trade stock every 13 days with the average trade being worth of $785,032. The most recent stock trade was executed by Vimal Kavuru on 25 September 2023, trading 676,371 units of ACST stock currently worth $1,251,286.

What does Acasti Pharma Inc do?

acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.

Acasti Pharma Inc executives and stock owners

Acasti Pharma Inc executives and other stock owners filed with the SEC include:

• Janelle D' Alvise,
  Pres, CEO, Corp. Sec. & Director
• Janelle D'Alvise,
  Pres, CEO, Corp. Sec. & Director
• Brian D. Ford CPA, CA,
  Chief Financial Officer
• Dr. Pierre Lemieux,
  Co-Founder, COO & Chief Scientific Officer
• Dr. Pierre Lemieux M.D., Ph.D.,
  Co-Founder, COO & Chief Scientific Officer
• Pierre Lemieux,
  Chief Operating Officer
• Donald Olds,
  Independent Director
• Jean-Marie Canan,
  Director
• Jean-Daniel Belanger,
  Secretary, Director- Corporate Affairs
• Brian Groch,
  Chief Commercial Officer
• Laurent Harvey,
  Vice President- Clinical and Non-Clinical Affairs
• Brian Ford,
  Chief Financial Officer
• Janelle D'Alvise,
  President, Chief Executive Officer, Director
• Roderick Carter,
  Executive Chairman of the Board
• Prashant Kohli,
  VP of Commercial Operations
• Dr. George Kottayil,
  Chief Operating Officer of US
• Dr. Yves Lachance Ph.D.,
  VP of Quality & Compliance
• Amresh Kumar,
  VP Clinical Operations
• R. Loch Macdonald,
  Chief Medical Officer
• Robert J Del Aversano,
  Principal Financial Officer
• Michael Derby,
  Director
• William A Haseltine,
  Director
• John Canan,
  Director
• Prashant Kohli,
  Chief Executive Officer
• Vimal Kavuru,
  
• A Brian Davis,
  
• George Kottayil,
  
• Edward Neugeboren,